KNSA: four filters pass, the first orphan-disease drug pick

Pass #25 in this channel's daily small-cap screen. Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is a UK-domiciled specialty biopharmaceutical company with one commercialized drug: ARCALYST (rilonacept), the only FDA-approved therapy for recurrent pericarditis (RP) — a rare inflammatory disease where the sac surrounding the heart repeatedly inflames. All four hard filters pass: $4.03B market cap ✅, 56.71% TTM revenue growth ✅, PEG 0.55 ✅ (caveat: StockAnalysis reports 1.06; discussed in the filter section), OCF +$165.86M ✅. 1 2

Two items belong at the top.

Caveat 1 — PEG source divergence. Finviz reports PEG 0.55, using a 5-year EPS growth estimate of 49.30%. StockAnalysis reports PEG 1.06, using a lower growth input. The filter passes under Finviz (the primary source for this series' small-cap PEG screen). Under StockAnalysis it is borderline at 1.06 — not a clear failure, but not a clean dual-source confirmation either. Both inputs are documented in the filter table below; readers relying on growth-adjusted valuation as a primary decision criterion should weigh the 1.06 figure. 1 2

Caveat 2 — single-product concentration. 100% of Kiniksa's product revenue comes from ARCALYST. Additionally, Regeneron Pharmaceuticals holds a 50/50 profit-sharing arrangement on ARCALYST, which consumed $75.6M of the $214.3M Q1 2026 revenue as collaboration expense — the company's single largest cost line. Every bull and bear argument in this note flows from that one product and that one partnership structure. 3

Current price: $52.34 (June 15, 2026 close). Pre-market June 16: $52.40. Market cap: $4.03B. 52-week range: $26.27–$59.87. YTD: +26.88%. 1-year: +84.95%.

Hard filter check

KNSA — hard screening metrics (TTM through March 31, 2026)

Three of four filters pass with dual-source confirmation. PEG passes under Finviz (0.55) but diverges under StockAnalysis (1.06) — documented below with full decomposition. OCF confirmed positive at $165.86M TTM.

Market cap

$0.00−59.7%vs $10B cap

TTM revenue growth

0.00+26.7%ppts above 30% threshold

PEG ratio (Finviz)

0.00−45.0%vs 1.0 threshold (SA: 1.06)

TTM operating cash flow

$0.00+0.0%positive; Q1 2026 OCF $50.2M

Loading stats card…

Filter	Threshold	Value	Source(s)	Status
Market cap	< $10B	$4.03B	Finviz, StockAnalysis	✅ Pass — dual-source aligned
TTM revenue growth	> 30%	56.71%	Finviz, StockAnalysis	✅ Pass — dual-source aligned
PEG ratio	< 1.0	0.55 (Finviz) / 1.06 (SA)	Finviz primary; StockAnalysis diverges	⚠️ Partial pass — source divergence
Operating cash flow	Positive	+$165.86M TTM	StockAnalysis	✅ Pass — confirmed

PEG decomposed: 1 2

Input	Finviz	StockAnalysis
Trailing P/E	57.68×	57.66×
Forward P/E	27.33×	41.29×
5-year EPS growth estimate	49.30%	Not disclosed (implied ~39% for PEG 1.06)
PEG (using respective Forward P/E)	0.55	1.06
TTM OCF	Implied positive (P/C ratio 8.60)	$165.86M

The divergence stems from different EPS growth inputs. Finviz uses 49.30% as the five-year forward EPS growth estimate for KNSA, which is derived from analyst consensus projections. StockAnalysis uses a lower figure — the exact input is not publicly disclosed, but backing into 1.06 from a common denominator suggests approximately 38–40% growth assumed. Both figures are analyst-estimate-based; neither is historical. This is documented as the single uncertainty in the filter panel.

What Kiniksa does

Kiniksa is incorporated in Bermuda and domiciled in the UK, trading as an American Depositary Share on NASDAQ. Its one approved drug, ARCALYST (rilonacept), received FDA approval in March 2021 for recurrent pericarditis — the first and only FDA-cleared therapy for that indication. ARCALYST is a weekly subcutaneous self-injection that works by trapping both interleukin-1α (IL-1α) and IL-1β — two inflammation-signaling proteins that drive RP episodes.

The disease context matters for understanding ARCALYST's market position. Recurrent pericarditis affects roughly 40,000 patients annually in the US; approximately 14,000 of those experience a second or subsequent recurrence refractory to first-line treatment (NSAIDs + colchicine). Standard second-line therapy — corticosteroids — is associated with up to 50% recurrence rates and frequent steroid dependence. ARCALYST enters after corticosteroid failure, providing a biologic alternative with strong Phase III data: the RHAPSODY trial showed roughly 7% recurrence rate on rilonacept versus 74% on placebo. 4

The business structure has one dominant feature: a 2017 license agreement with Regeneron Pharmaceuticals, from which Kiniksa licensed ARCALYST. Under that agreement, Kiniksa and Regeneron split ARCALYST profits 50/50 after commercialization expenses. This profit-sharing structure is the central lens through which all margin and cash flow metrics must be read. 3

Five quarters of revenue

ARCALYST revenue has accelerated every quarter since Q1 2025:

Loading chart…

Quarter	Revenue	YoY growth	Net income	Diluted EPS
Q1 2025	$137.8M	—	$8.5M	$0.11
Q2 2025	$156.8M	—	—	$0.23
Q3 2025	$180.9M	—	—	$0.23
Q4 2025	$202.1M	—	—	$0.17
Q1 2026	$214.3M	+55.5% YoY	$22.6M	$0.27
FY2025	$677.6M	+60.1% vs. FY2024	—	$0.75
FY2026E	$930–945M (guidance)	~+37–40% implied	—	$1.20 (consensus)

TTM revenue (Q2 2025–Q1 2026): $754.05M. The FY2026 guidance of $930M–$945M, raised April 28, 2026 from a prior range of $900–$920M, implies ARCALYST is approaching $1B in annual revenue — blockbuster status for a biologic targeting a rare orphan indication with roughly 14,000 eligible US patients per year. 3 5

CEO Sanj K. Patel noted the expansion beyond existing prescribers: "Five years from launch, Kiniksa continues to deliver strong ARCALYST revenue growth, driven by expanding adoption of IL-1α and IL-1β inhibition for recurrent pericarditis." 3 More than 4,500 unique prescribers have written ARCALYST since launch; average patient treatment duration is approaching three years, consistent with the median disease course.

Valuation

KNSA's trailing multiples are elevated by specialty pharma standards. The PEG ratio is the one metric that justifies the earnings-based premium — it requires the 49.30% five-year EPS growth estimate (Finviz) to materialize.

KNSA — valuation snapshot (price $52.34, June 15, 2026)

Trailing multiples are high; PEG and forward P/E are the bull case's load-bearing metrics. EV is below market cap due to $459M net cash, which accounts for roughly 11% of market cap.

Trailing P/E

0.00+0.0%EPS TTM $0.90–$0.91

Forward P/E

0.00+0.0%Finviz; SA: 41.29×

EV/EBITDA

0.00+0.0%EV $3.57B (cash-rich)

P/FCF

0.00+0.0%Both sources agree

P/S (TTM)

0.00+0.0%TTM rev $754M

Loading stats card…

Metric	Finviz	StockAnalysis	Notes
Trailing P/E	57.68×	57.66×	High; profits still growing off a small base
Forward P/E	27.33×	41.29×	Divergence due to different FY2026/2027 EPS consensus sets
EV/EBITDA	37.60×	—	EV $3.57B (market cap $4.03B minus net cash $0.46B)
P/S (TTM)	5.34×	—	TTM revenue $754M
P/FCF	24.52×	24.52×	Both sources agree
P/OCF	24.28×	24.28×	Both sources agree
P/B	6.63×	6.37×	Book value per share $7.90–$8.22
PEG	0.55	1.06	See filter section

The EV/EBITDA of 37.6× is high for a specialty pharma, though it needs context: ARCALYST's gross margin reported by Finviz is 54.61% — low for a biologic, because the Regeneron profit-sharing flows through collaboration expense above the gross line. True pharmaceutical gross margins for ARCALYST itself are higher, but the after-profit-split economics are what investors actually own. The P/FCF of 24.5× is more defensible, given that FCF is generated in substantial real dollar terms ($165.86M TTM OCF, $24.28 P/OCF). 1 2

Balance sheet

Metric	Value (March 31, 2026)	Context
Cash + short-term investments	$468.1M	Up from $414.1M at Dec 31, 2025
Total debt	$9.03M	Minimal; likely lease-related
Net cash	$459.1M ($5.97/share)	Effectively debt-free
D/E ratio	0.01	No leverage concern
Current ratio	3.79×	Finviz and StockAnalysis agree
Working capital	$437.6M
Shareholders' equity	$605.7M	Accumulated deficit $(439.5M) from pre-profitability phase
Altman Z-Score	8.44	Well above distress zone (threshold: 2.99)
Piotroski F-Score	7 / 9	Positive signal on financial health

The balance sheet is unusually clean for a specialty pharma. Net cash of $459M is growing: cash increased $54M in the single quarter from December 2025 to March 2026, funded entirely by operating cash flow. No debt issuance, no equity dilution. The Altman Z-Score of 8.44 and Piotroski F-Score of 7 both indicate strong financial health on quantitative screens. 2 3

Growth catalysts

1. 13% patient penetration in a growing market. ARCALYST captured roughly 13% of eligible US recurrent pericarditis patients in 2024. Even assuming the Regeneron 50/50 split and full commercialization costs, moving from 13% to 20% penetration on the same per-patient economics could add hundreds of millions in incremental revenue. The global pericarditis therapy market was estimated at $3.6–$4.1B in 2025 and is projected to reach $6–$7B by 2035. 4

2. "Heart's Home" DTC campaign launched April 2026. On April 8, 2026, Kiniksa launched its first direct-to-consumer TV advertising campaign for ARCALYST, titled "Heart's Home," on connected TV and streaming platforms. The campaign aims to drive patients to discuss ARCALYST with their cardiologist — an awareness-to-prescription funnel that should compound over time. Management has not yet disclosed campaign-specific patient acquisition metrics, as the campaign is less than three months old. 6

Kiniksa "Heart's Home" DTC campaign announcement, April 2026 — Kiniksa's first direct-to-consumer TV campaign for ARCALYST, launched April 8, 2026. 6

3. KPL-387: the wholly-owned next-generation candidate. Kiniksa independently developed KPL-387, a fully human IgG2 monoclonal antibody targeting IL-1R1 — the same receptor pathway as ARCALYST, but designed for monthly subcutaneous self-injection in liquid form. The key commercial distinction: if KPL-387 is approved, Kiniksa captures 100% of the economics versus the 50/50 ARCALYST split with Regeneron. FDA granted KPL-387 Orphan Drug Designation in October 2025. Phase 2 dose-focusing data is expected in the second half of 2026; Phase 3 pivotal trial is planned to start by year-end 2026. 7

CEO Patel stated at Q1 2026 earnings: "Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 trial in recurrent pericarditis remain on track for the second half of 2026. Furthermore, we expect to initiate the Phase 3 pivotal trial by the end of this year." 3

4. Method-of-use patent through 2039. The composition of matter patent on the rilonacept molecule expired in 2020, but US Patent No. 11,026,997 — covering methods of using ARCALYST in recurrent pericarditis — expires March 11, 2039. This extends IP protection approximately 11 years beyond ARCALYST's orphan drug exclusivity (which runs to 2028). As a biologic, ARCALYST faces a biosimilar pathway rather than a small-molecule generic pathway, providing additional practical barriers to entry. 8

Key risks

Risk	Severity	Impact path
PEG divergence between data sources	🔴 High (for PEG-reliant investors)	Finviz PEG 0.55 vs. StockAnalysis 1.06. The filter passes under the series' primary source (Finviz), but readers who weight the StockAnalysis figure should treat the valuation as growth-neutral rather than growth-discounted. If FY2026 EPS consensus ($1.20) is revised downward further — it already dropped from $1.52 ninety days prior — both PEG inputs would worsen. 2
Single-product concentration + Regeneron profit split	🔴 High	100% of revenue from ARCALYST. Regeneron collaboration expense was $75.6M in Q1 2026 alone — 35% of revenue. Any ARCALYST disruption (clinical, regulatory, competitive) directly impairs cash generation with no diversification buffer. The profit-sharing also structurally caps net margin expansion as revenue scales: each incremental revenue dollar gets split before it reaches the income statement. 3
FY2026 EPS consensus revision trend	🟡 Medium	FY2026 GAAP EPS consensus has fallen from $1.52 ninety days ago to $1.20 currently — a 21% downward revision in a single quarter. The cause is not disclosed in research data, but a downward EPS revision trend concurrent with revenue acceleration suggests cost or non-recurring item pressures. The revision matters because the PEG depends directly on EPS growth assumptions. 2 9
Heavy insider selling, no open-market buying	🟡 Medium	CEO Sanj Patel sold over $25M in shares in late April 2026 at prices in the $43–$54 range. CMO John Paolini, Director Barry Quart, and CFO Mark Ragosa also sold. All transactions appear to be planned Rule 10b5-1 or option exercise + immediate sale. No open-market insider purchases have been filed by any officer or director. The -2.25% insider transaction trend (Finviz) contrasts with the +3.37% institutional transaction trend, suggesting institutional buyers are absorbing insider supply. 10
Competitive pipeline in pericarditis	🟡 Medium	Several potential competitors are in clinical development: canakinumab (Novartis, IL-1β mAb, Phase II), goflikicept/RPH-104 (R-Pharm, Phase II/III), CardiolRx (Cardiol Therapeutics, oral cannabidiol-based NLRP3 modulator, Phase III MAVERIC trial), and VTX2735 (Ventyx Biosciences, oral NLRP3 inhibitor, Phase II). Oral agents in particular could represent a convenience-based competitive threat if efficacy is confirmed — daily injection (anakinra, off-label) or weekly injection (ARCALYST) versus a daily oral pill is a different value proposition for patients. 4
KPL-387 Phase 2 binary risk	🟡 Medium	The KPL-387 Phase 2 data in H2 2026 is both the key catalyst and a binary risk event. If Phase 2 dose-focusing results do not support a clear dose and efficacy signal for Phase 3, the wholly-owned pipeline thesis fails. Phase 3 data would then be multiple years away, and the long-term bull case (100% economics, monthly dosing) would be substantially de-risked as a near-term story. 7
UK domicile and foreign private issuer status	🟢 Low-medium	KNSA is incorporated in Bermuda, domiciled in the UK, and trades as a foreign private issuer (FPI) on NASDAQ. FPI status means less frequent SEC disclosure (20-F annual vs. 10-K), different governance exemptions, and exposure to UK tax law changes and US/UK tax treaty uncertainty. The practical risk in the near term is transparency — FPI filings have longer reporting lags than domestic issuers. 11

Analyst consensus and price action

8 analysts cover KNSA. All 8 carry a Buy or Strong Buy rating (Finviz recommendation score: 1.00 = Strong Buy). Average price target: $63.50, implying +21.3% upside from $52.34. 1 9

Recent target changes around the May 2026 earnings cycle: Jefferies raised to $71 (from $58), Citi raised to $60 (from $50), Canaccord raised to $64 (from $62), Wedbush raised to $59 (from $58). Earlier initiations: TD Cowen Buy at $60 (September 2025), Canaccord Buy at $62 (February 2026). The pattern is a modest upward drift in targets, but 21% upside from current levels is relatively tight compared to this series' prior picks — a reflection of the stock's 84.95% one-year run.

One metric warrants attention: beta of 0.11–0.12 (five-year). KNSA has moved almost entirely independently of the broad market over the past five years. This makes it an unusual small-cap screen result: most of the stocks in this series exhibit beta in the 0.7–1.5 range. The low beta stems from ARCALYST's status as an orphan disease drug with insurance-covered recurring revenue — it does not track macro risk cycles the way a cyclical business would.

Price action: $52.34 close June 15. RSI 55.12 (neutral). The stock is 12.6% below its 52-week high of $59.87 and 99.2% above its 52-week low of $26.27. All three moving averages trend upward: price is 3.06% above the 20-day, 3.05% above the 50-day, and 19.84% above the 200-day. Short interest: 7.02% of float (3.04M shares), 4.58 days to cover — moderate, not a crowded short. 1 2

Insider and institutional ownership

Institutional ownership: 59.45% (Finviz) / 56.19% (StockAnalysis). 327 institutions hold KNSA as of March 31, 2026. Institutional transaction trend is positive at +3.37% over the measured period. 10

Top 5 institutional holders (as of March 31, 2026):

Holder	Shares	% of outstanding	Approx. value
FMR LLC (Fidelity)	6.82M	16.93%	~$357M
Rubric Capital Management	3.75M	9.30%	~$196M
Baker Bros. Advisors	2.83M	7.01%	~$148M
Tang Capital Management	2.26M	5.61%	~$118M
Vanguard Portfolio Management	1.77M	4.38%	~$92M

Baker Bros. Advisors is a dedicated life sciences fund known for concentrated, long-duration positions in specialty pharma. Its presence as a top-3 holder is a signal worth noting relative to generalist institutional ownership patterns. 10

Insider ownership: 43.67% (Finviz, all share classes) vs. 4.58% (StockAnalysis, likely common shares only) vs. 3.58% (Yahoo Finance). The discrepancy reflects KNSA's dual-class share structure. The Finviz 43.67% figure includes share classes held by founders and controlling shareholders; the StockAnalysis and Yahoo figures are likely limited to publicly traded common shares.

Insider transactions: Heavy selling by CEO Patel ($25M+ in late April 2026), CMO Paolini, Director Quart, and CFO Ragosa — all at prices in the $43–$54 range, and all appearing to be pre-planned Rule 10b5-1 or option exercise + immediate sale transactions. Insider transaction net: -2.25% (Finviz). No open-market purchases by any officer or director are on record. 10

Upcoming catalysts

Catalyst	Expected timing	What to watch
Q2 2026 earnings	~July 28, 2026 (pre-market, per StockAnalysis)	Revenue vs. consensus $226.5M (+44% YoY); GAAP EPS vs. $0.29 consensus; any DTC campaign commentary; updated FY2026 guidance
KPL-387 Phase 2 dose-focusing data	H2 2026	Dose selection signal; safety and tolerability data; Phase 3 go/no-go decision
KPL-387 Phase 3 initiation	By end of 2026	Confirms Phase 2 success; triggers multi-year development and regulatory timeline
KPL-1161 Phase 1 (quarterly-dosing candidate)	By end of 2026	First-in-human data for the next-generation quarterly injection format
DTC campaign metrics	Q2 2026 earnings call	Management commentary on new patient starts, physician consultation rates

All catalyst dates sourced from: 3 2

The bottom line on Pass #25

Kiniksa passes all four hard filters — with the documented PEG caveat. The business has a profile that is rare among small-cap screen results: one drug, one indication, one revenue line growing at 57% TTM, a fortress balance sheet with $459M net cash and essentially zero debt, and Altman Z-Score of 8.44. The Regeneron 50/50 profit split is real and structural, but it hasn't stopped the company from generating $165M in TTM operating cash flow.

The bull case has two components. The near-term story is penetration: ARCALYST reached only 13% of eligible US patients in 2024, and both the DTC campaign and a growing prescriber base (4,500+ unique writers since launch, still expanding) suggest the ceiling is not close. The longer-term story is KPL-387: if Phase 2 data in H2 2026 supports Phase 3, Kiniksa would be positioned to replace its 50/50 split product with a wholly-owned therapy on the same indication — capturing twice the per-patient economics and retaining full pricing control.

The bear case is also straightforward. The PEG passes under one of two sources. EPS consensus has been revised down 21% in ninety days, and FY2026 EPS of $1.20 against a $52.34 stock price is a trailing P/E of 57.7× — expensive if the growth story experiences any interruption. The insider selling pattern — CEO Patel alone sold $25M+ in April 2026 at prices near the current level — is the clearest near-term sentiment signal that insiders are not buyers at this price.

At $52.34, the 8-analyst consensus target of $63.50 implies 21.3% upside. That is the tightest consensus-to-price gap in this series, which is consistent with the stock's 84.95% one-year run. The next checkpoint is July 28, 2026 Q2 earnings — where ARCALYST's trajectory against the raised $930–$945M guidance, and any DTC campaign commentary, will determine whether the current multiple is sustainable.

Cover image: AI-generated illustration.

Data as of June 15–16, 2026. This article is a screening note and does not constitute investment advice.